Early add-on Vildagliptin in Patients With Type 2 Diabetes Inadequately Controlled by Metformin
Phase 4
Completed
- Conditions
- Type-2 Diabetes Mellitus
- Interventions
- Drug: LAF237 (vildagliptin)
- First Posted Date
- 2013-01-11
- Last Posted Date
- 2017-05-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 117
- Registration Number
- NCT01766778
- Locations
- 🇭🇰
Novartis Investigative Site, Tuen Mun, Hong Kong
Effect of Hepatic Impairment on LDE225..
- First Posted Date
- 2013-01-10
- Last Posted Date
- 2020-12-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 33
- Registration Number
- NCT01764776
- Locations
- 🇺🇸
University of Miami Div. of Clinical Pharmacology, Miami, Florida, United States
🇮🇱Novartis Investigative Site, Tel-Aviv, Israel
Eltrombopag Phase III Study In Chinese Chronic ITP Patients
Phase 3
Completed
- Conditions
- Purpura, Thrombocytopenic, Idiopathic and Hepatitis C
- Interventions
- Drug: placebo
- First Posted Date
- 2013-01-08
- Last Posted Date
- 2019-12-03
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 155
- Registration Number
- NCT01762761
- Locations
- 🇨🇳
Novartis Investigative Site, Tianjin, China
A Phase I Dose Escalation Study of CGM097 in Adult Patients With Selected Advanced Solid Tumors
- First Posted Date
- 2013-01-04
- Last Posted Date
- 2021-06-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 51
- Registration Number
- NCT01760525
- Locations
- 🇺🇸
Dana Farber Cancer Institute SC (2), Boston, Massachusetts, United States
🇨🇭Novartis Investigative Site, Zuerich, Switzerland
Vildagliptin Compared to Gliclazide as Dual Therapy With Metformin in Muslim Patients With Type 2 Diabetes Fasting During Ramadan
Phase 4
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2013-01-01
- Last Posted Date
- 2013-10-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 557
- Registration Number
- NCT01758380
- Locations
- 🇬🇧
Novartis Investigative Site, Manchester, United Kingdom
Fingolimod (FTY720) in Acute Demyelinating Optic Neuritis (ADON)
Phase 2
Terminated
- Conditions
- Acute Demylelinating Optic Neuritis
- Interventions
- Drug: Placebo
- First Posted Date
- 2012-12-31
- Last Posted Date
- 2015-05-04
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 2
- Registration Number
- NCT01757691
- Locations
- 🇪🇸
Novartis Investigative Site, Majadahonda, Madrid, Spain
Safety and Efficacy of NVA237 as an add-on to Fixed Dose Combination LABA/ICS
Phase 3
Withdrawn
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Drug: Placebo to NVA237
- First Posted Date
- 2012-12-28
- Last Posted Date
- 2017-04-20
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT01757015
Efficacy, Safety, Tolerability and Pharmacokinetics of KAF156 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-infection
- First Posted Date
- 2012-12-20
- Last Posted Date
- 2018-06-07
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 43
- Registration Number
- NCT01753323
- Locations
- 🇻🇳
Novartis Investigative Site, Hanoi, Vietnam
Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis
- First Posted Date
- 2012-12-19
- Last Posted Date
- 2020-05-13
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 397
- Registration Number
- NCT01752634
- Locations
- 🇬🇧
Novartis Investigative Site, Southampton, United Kingdom
BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC)
Phase 1
Completed
- Conditions
- Cancer
- Interventions
- First Posted Date
- 2012-12-17
- Last Posted Date
- 2021-10-29
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 166
- Registration Number
- NCT01750918
- Locations
- 🇬🇧
Novartis Investigative Site, Birmingham, United Kingdom